Omkar Speciality Chemicals exits CIRP: key 2026 steps

Omkar Speciality Chemicals Limited has exited the Corporate Insolvency Resolution Process (CIRP) after the National Company Law Tribunal (NCLT) approved its resolution plan on July 31, 2025. With the approval in place, control of the company has moved to a newly appointed Board of Directors and reconstituted committees, as the company works through the steps required to implement the plan.

The immediate takeaway for investors is that, despite the formal exit from insolvency proceedings, the company’s reported operating performance for the quarters ended June 30, September 30, and December 31, 2025 remained weak, with zero revenue from operations and continuing quarterly losses.

NCLT approval and what it changes

The turning point came on July 31, 2025, when the NCLT Mumbai bench approved the resolution plan for Omkar Speciality Chemicals. The plan was submitted by Kshitij Polyline Limited, which emerged as the successful resolution applicant. Following the order, the company’s corporate control transitioned away from the earlier insolvency framework and towards the new management structure tasked with executing the revival plan.

This matters because an NCLT-approved resolution plan is the legal basis for actions such as capital reduction, fresh issuance of shares, settlement of eligible claims, and extinguishment of claims not covered under the plan. The company has also indicated that committees such as the Audit Committee and the Stakeholder’s Relationship Committee have been reconstituted after the change in control.

Key financial terms of the resolution plan

As disclosed, the plan involves a total resolution amount of ₹26.65 crore. By September 2025, ₹9.734 crore had already been infused. The plan’s structure was also described as including ₹4.75 crore of equity and ₹21.9 crore of loans, adding up to the same ₹26.65 crore total infusion.

Separately, the plan disclosures include a payout of ₹23.14 crore to creditors, including ₹21.76 crore to secured lenders. The plan also references payment to operational creditors of ₹0.064 crore (₹6.4 lakh), stated as being above liquidation value.

Capital restructuring: five steps outlined to exchanges

Omkar Speciality Chemicals has communicated a five-step capital restructuring plan as part of the insolvency resolution process. The plan includes:

1. Complete capital reduction to NIL, as per the NCLT order dated July 31, 2025.
2. Fresh equity issuance to the resolution applicant at a face value of ₹10.
3. Seeking in-principle approvals from stock exchanges.
4. Share allotment that results in the resolution applicant holding 100% of the paid-up capital.
5. Achieving minimum public shareholding through a 5% offer-for-sale (OFS) mechanism.

The company stated it will seek stock exchange approvals before implementing the share allotment process. The capital restructuring plan was communicated to BSE Limited and the National Stock Exchange of India Limited on April 28, 2026 by Ajit Kumar, Chairperson of the Monitoring Committee.

Record date and cancellation of existing shares

In line with the approved plan, the monitoring committee convened on April 15, 2026 and set April 29, 2026 as the record date for the extinguishment and cancellation of all existing equity shares. On the record date, all shares held by promoters, promoter groups, and public shareholders, with a face value of ₹10 each, are to be cancelled.

Simultaneously, the company plans to issue 50 lakh new equity shares to IFFAS Kshitij SPV LLP at par value on a private placement basis, raising ₹5 crore in cash. This is intended to result in IFFAS Kshitij SPV LLP assuming complete ownership of Omkar Speciality Chemicals.

Borrowing facility and funding recognition

For operational continuity, the monitoring committee approved a borrowing facility of up to ₹20 crore from Kshitij Polyline Limited, classified as non-convertible. The disclosures also note that earnest money deposited by the successful resolution applicant before NCLT approval will be recognised as part of the ₹21.9 crore funding package under the resolution plan.

These steps highlight that the plan is not limited to capital actions alone, but also includes arrangements to fund near-term requirements through a borrowing line.

What the 2025 quarterly numbers show

The company’s financial results for the quarters ended June 30, September 30, and December 31, 2025 showed zero revenue from operations. Losses continued, ranging from ₹0.3284 crore to ₹0.5179 crore per quarter. Basic EPS for these quarters was reported in a range of negative ₹0.16 to negative ₹0.25.

While the company has exited CIRP, these numbers underline that the revival remains execution-dependent and will be judged on whether operations restart and revenues return.

Monitoring Committee meeting scheduled for May 27, 2026

Omkar Speciality Chemicals stated that its Monitoring Committee will meet on May 27, 2026 to approve unaudited financials for the quarters ended June, September, and December 2025. The stated focus of the meeting is the review and approval of financial records, including the unaudited financial statements for the three specific quarters.

This meeting is a procedural step, but it is also important for timely disclosure and for stakeholders tracking the post-resolution transition.

Tribunal’s ruling on creditor disputes

The NCLT Mumbai Bench, comprising Hon’ble Shri Ashish Kalia (Member Judicial) and Hon’ble Shri Sanjiv Dutt (Member Technical), approved the resolution plan and dismissed applications from dissenting financial creditors Axis Bank Ltd. and NKGSB Co-operative Bank Ltd. The ruling reinforced the Committee of Creditors’ (CoC) commercial wisdom in determining distribution of resolution proceeds.

The tribunal held that distributing proceeds based on security value was within the CoC’s commercial wisdom and is sanctioned by Section 30(4) of the Insolvency and Bankruptcy Code (IBC). It also reiterated that a dissenting creditor cannot demand more than its liquidation value entitlement under the Code.

CIRP timeline and background

Omkar Speciality Chemicals was admitted into CIRP via an order dated December 5, 2022. The company is described as a Thane-based manufacturer of specialty chemicals. Its liquidation value was estimated at ₹13.15 crore.

In 2024, the CoC approved Kshitij Polyline’s resolution plan with 83% favourable votes, with Bank of Baroda (BoB) indicated as leading the CoC. Separately, the NCLT also directed the Resolution Professional and BoB to provide the erstwhile director with a detailed break-up of BoB’s claim amounting to ₹290.05 crore, citing the importance of transparency in insolvency proceedings.

Disclosures flagging inventory valuation impact

The financial statement notes included an “Emphasis of Matters” item stating that the company changed the method of arriving at the cost of work in progress and finished goods during the year under review. This change resulted in an under-statement of stock and profit by ₹0.6568 crore (₹65.68 lakh). The note also stated the opinion was not modified in respect of this matter.

Key facts at a glance

Why this matters for investors and the sector

For public market investors, Omkar Speciality Chemicals’ case highlights the sharp distinction between a legal milestone and an operating turnaround. Exiting CIRP and getting the capital structure reset can remove legacy constraints, but reported numbers still show no operating revenue in the cited quarters and continuing losses.

For the broader insolvency ecosystem, the NCLT’s order on creditor objections reinforces the primacy of security interest value in distributions and the deference given to CoC decision-making. That is relevant to how recovery expectations get set, especially where primary and secondary secured creditors have conflicting views on payout allocation.

Conclusion

Omkar Speciality Chemicals has formally exited CIRP following the NCLT’s July 31, 2025 approval, and the company has outlined a capital restructuring plan that includes cancelling existing shares and issuing new equity to IFFAS Kshitij SPV LLP. The next near-term marker is the Monitoring Committee meeting on May 27, 2026 to approve unaudited financials for the June, September, and December 2025 quarters, as the new management works to execute the revival plan.